{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:52:13Z","timestamp":1788306733196,"version":"build-2803163510"},"reference-count":191,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of University and Research (MUR)","award":["PRIN-2022 n. 20223K7L88"],"award-info":[{"award-number":["PRIN-2022 n. 20223K7L88"]}]},{"name":"Italian Ministry of University and Research (MUR)","award":["PRIN-2022-PNRR n. 20227JB3W"],"award-info":[{"award-number":["PRIN-2022-PNRR n. 20227JB3W"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disorder characterized by progressive cholestatic that, if untreated, can progress to liver fibrosis, cirrhosis and liver decompensation requiring liver transplant. Although the pathogenesis of the disease is multifactorial, there is a consensus that individuals with a genetic predisposition develop the disease in the presence of specific environmental triggers. A dysbiosis of intestinal microbiota is increasingly considered among the potential pathogenic factors. Cholangiocytes, the epithelial cells lining the bile ducts, are the main target of a dysregulated immune response, and cholangiocytes senescence has been recognized as a driving mechanism, leading to impaired bile duct function, in disease progression. Bile acids are also recognized as playing an important role, both in disease development and therapy. Thus, while bile acid-based therapies, specifically ursodeoxycholic acid and obeticholic acid, have been the cornerstone of therapy in PBC, novel therapeutic approaches have been developed in recent years. In this review, we will examine published and ongoing clinical trials in PBC, including the recently approved peroxisome-proliferator-activated receptor (PPAR) agonist, elafibranor and seladelpar. These novel second-line therapies are expected to improve therapy in PBC and the development of personalized approaches.<\/jats:p>","DOI":"10.3390\/cells13181580","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:51:46Z","timestamp":1726746706000},"page":"1580","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Current Landscape and Evolving Therapies for Primary Biliary Cholangitis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-4222","authenticated-orcid":false,"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Urbani","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Di Giorgio","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-6896","authenticated-orcid":false,"given":"Michele","family":"Biagioli","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[{"name":"SC di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional Variation and Temporal Trend of Primary Biliary Cholangitis Epidemiology: A Systematic Review and Meta-Analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"Achufusi, T.G.O., Safadi, A.O., and Mahabadi, N. (2024). Ursodeoxycholic Acid, StatPearls Publishing."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.hepres.2005.09.029","article-title":"Hepatoprotective Bile Acid \u201cursodeoxycholic Acid (UDCA)\u201d Property and Difference as Bile Acids","volume":"33","author":"Ishizaki","year":"2005","journal-title":"Hepatol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1572-0241.1998.00287.x","article-title":"Autoimmune Conditions Associated with Primary Biliary Cirrhosis: Response to Ursodeoxycholic Acid Therapy","volume":"93","author":"Zukowski","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lleo, A., Jepsen, P., Morenghi, E., Carbone, M., Moroni, L., Battezzati, P.M., Podda, M., Mackay, I.R., Gershwin, M.E., and Invernizzi, P. (2016). Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Sci. Rep., 6.","DOI":"10.1038\/srep25906"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24691","article-title":"A Biliary HCO3\u2212 Umbrella Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Human Cholangiocytes","volume":"55","author":"Hohenester","year":"2012","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-Based Studies","volume":"20","author":"Trivedi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic Acid Therapy and Liver Transplant-Free Survival in Patients with Primary Biliary Cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1535370217748893","article-title":"Environmental Basis of Primary Biliary Cholangitis","volume":"243","author":"Tanaka","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12328-017-0799-z","article-title":"Genetics and Epigenetics in the Pathogenesis of Primary Biliary Cholangitis","volume":"11","author":"Joshita","year":"2018","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary Biliary Cirrhosis in Monozygotic and Dizygotic Twins: Genetics, Epigenetics, and Environment","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1542-3565(04)00678-0","article-title":"From Bases to Basis: Linking Genetics to Causation in Primary Biliary Cirrhosis","volume":"3","author":"Invernizzi","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/0016-5085(91)90090-8","article-title":"HLA DRw8 and Complement C4 Deficiency as Risk Factors in Primary Biliary Cirrhosis","volume":"101","author":"Manns","year":"1991","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1399-0039.1994.tb02303.x","article-title":"Genes within the HLA Class II Region Confer Both Predisposition and Resistance to Primary Biliary Cirrhosis","volume":"43","author":"Begovich","year":"1994","journal-title":"Tissue Antigens"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0168-8278(00)80213-5","article-title":"CTLA-4 Gene Polymorphism Confers Susceptibility to Primary Biliary Cirrhosis","volume":"32","author":"Agarwal","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/gut.48.3.397","article-title":"HLA and Interleukin 1 Gene Polymorphisms in Primary Biliary Cirrhosis: Associations with Disease Progression and Disease Susceptibility","volume":"48","author":"Donaldson","year":"2001","journal-title":"Gut"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/0891693021000056703","article-title":"Association of Single Nucleotide Polymorphisms of the Interleukin-10 Promoter Gene and Susceptibility to Primary Biliary Cirrhosis: Immunogenetic Differences in Italian and Japanese Patients","volume":"35","author":"Matsushita","year":"2002","journal-title":"Autoimmunity"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mulinacci, G., Palermo, A., Gerussi, A., Asselta, R., Gershwin, M.E., and Invernizzi, P. (2022). New Insights on the Role of Human Leukocyte Antigen Complex in Primary Biliary Cholangitis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.975115"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ajhg.2012.08.010","article-title":"Genome-Wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population","volume":"91","author":"Nakamura","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpg.2018.05.008","article-title":"Evolution of Our Understanding of PBC","volume":"34\u201335","author":"Tanaka","year":"2018","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clinre.2011.07.013","article-title":"Urinary Tract Infection as a Risk Factor for Autoimmune Liver Disease: From Bench to Bedside","volume":"36","author":"Smyk","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Shamriz, O., Nussinovitch, U., and Rose, N.R. (2017). Chapter 1\u2014Pathophysiology of Autoimmunity and Immune-Mediated Mechanisms in Cardiovascular Diseases. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases, Academic Press.","DOI":"10.1016\/B978-0-12-803267-1.00001-6"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/hep.20491","article-title":"Sidechain Biology and the Immunogenicity of PDC-E2, the Major Autoantigen of Primary Biliary Cirrhosis","volume":"40","author":"Mao","year":"2004","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0168-8278(03)00501-4","article-title":"Microbial Mimics Are Major Targets of Crossreactivity with Human Pyruvate Dehydrogenase in Primary Biliary Cirrhosis","volume":"40","author":"Bogdanos","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2004.41121.x","article-title":"Novosphingobium Aromaticivorans: A Potential Initiator of Primary Biliary Cirrhosis","volume":"99","author":"Kaplan","year":"2004","journal-title":"Off. J. Am. Coll. Gastroenterol.|ACG"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/jhep.2003.50446","article-title":"Patients with Primary Biliary Cirrhosis React against a Ubiquitous Xenobiotic-Metabolizing Bacterium","volume":"38","author":"Selmi","year":"2003","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","article-title":"Risk Factors and Comorbidities in Primary Biliary Cirrhosis: A Controlled Interview-Based Study of 1032 Patients","volume":"42","author":"Gershwin","year":"2005","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-1007183","article-title":"Antimitochondrial Antibodies in Primary Biliary Cirrhosis","volume":"17","author":"Leung","year":"1997","journal-title":"Semin. Liver Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0168-8278(01)80793-5","article-title":"Epitope Specificity of Anti-PDC E1 Alpha Antibodies in Primary Biliary Cirrhosis (PBC)","volume":"34","author":"Palmer","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1365-2249.2000.01403.x","article-title":"Secretory Autoantibodies in Primary Biliary Cirrhosis (PBC)","volume":"122","author":"Palmer","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1568-9972(03)00013-2","article-title":"Antinuclear Antibodies Specific for Primary Biliary Cirrhosis","volume":"2","author":"Worman","year":"2003","journal-title":"Autoimmun. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(00)00040-4","article-title":"Autoantibodies against Nuclear Pore Complexes Are Associated with More Active and Severe Liver Disease in Primary Biliary Cirrhosis","volume":"34","author":"Invernizzi","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2152\/jmi.64.7","article-title":"Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological Mechanisms","volume":"64","author":"Tsuneyama","year":"2017","journal-title":"J. Med. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.181.2.723","article-title":"Heterogeneity of Autoreactive T Cell Clones Specific for the E2 Component of the Pyruvate Dehydrogenase Complex in Primary Biliary Cirrhosis","volume":"181","author":"Ansari","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaut.2010.06.004","article-title":"Phenotypical and Functional Alterations of CD8 Regulatory T Cells in Primary Biliary Cirrhosis","volume":"35","author":"Bernuzzi","year":"2010","journal-title":"J. Autoimmun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00795-006-0321-z","article-title":"Molecular Mechanisms of Cholangiopathy in Primary Biliary Cirrhosis","volume":"39","author":"Harada","year":"2006","journal-title":"Med. Mol. Morphol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2249.2009.03947.x","article-title":"Periductal Interleukin-17 Production in Association with Biliary Innate Immunity Contributes to the Pathogenesis of Cholangiopathy in Primary Biliary Cirrhosis","volume":"157","author":"Harada","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/cei\/uxad117","article-title":"Regulatory T Cells in Inflamed Liver Are Dysfunctional in Murine Primary Biliary Cholangitis","volume":"215","author":"Lin","year":"2024","journal-title":"Clin. Exp. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cphy.c120019","article-title":"Physiology of Cholangiocytes","volume":"3","author":"Tabibian","year":"2013","journal-title":"Compr. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ar.20664","article-title":"Functional Anatomy of Normal Bile Ducts","volume":"291","author":"Strazzabosco","year":"2008","journal-title":"Anat. Rec."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Masyuk, A.I., Masyuk, T.V., and LaRusso, N.F. (2018). Chapter 44\u2014Physiology of Cholngiocytes. Physiology of the Gastrointestinal Tract, Academic Press. [6th ed.].","DOI":"10.1016\/B978-0-12-809954-4.00044-X"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.4049\/jimmunol.175.11.7447","article-title":"Multiple TLRs Are Expressed in Human Cholangiocytes and Mediate Host Epithelial Defense Responses to Cryptosporidium Parvum via Activation of NF-KappaB","volume":"175","author":"Chen","year":"2005","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcmgh.2015.05.005","article-title":"Functional and Structural Features of Cholangiocytes in Health and Disease","volume":"1","author":"Maroni","year":"2015","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/JLB.5MR0320-200R","article-title":"Immune System and Cholangiocytes: A Puzzling Affair in Primary Biliary Cholangitis","volume":"108","author":"Ronca","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_48","first-page":"1221","article-title":"Transforming Growth Factors Beta 1 and Beta 2 Are Differentially Expressed in Fibrotic Liver Disease","volume":"139","author":"Milani","year":"1991","journal-title":"Am. J. Pathol."},{"key":"ref_49","first-page":"G765","article-title":"Secretion of MCP-1\/CCL2 by Bile Duct Epithelia Induces Myofibroblastic Transdifferentiation of Portal Fibroblasts","volume":"290","author":"Kruglov","year":"2006","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbadis.2017.07.024","article-title":"Role of Inflammation and Proinflammatory Cytokines in Cholangiocyte Pathophysiology","volume":"1864","author":"Pinto","year":"2018","journal-title":"Biochim. Biophys. Acta\u2014Mol. Basis Dis."},{"key":"ref_51","first-page":"G1077","article-title":"Advances in Cholangiocyte Immunobiology","volume":"303","author":"Syal","year":"2012","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep.1840200217","article-title":"Human Biliary Epithelial Cells Secrete and Respond to Cytokines and Hepatocyte Growth Factors in Vitro: Interleukin-6, Hepatocyte Growth Factor and Epidermal Growth Factor Promote DNA Synthesis in Vitro","volume":"20","author":"Matsumoto","year":"1994","journal-title":"Hepatology"},{"key":"ref_53","first-page":"403720","article-title":"A Review of the Physiological and Immunological Functions of Biliary Epithelial Cells: Targets for Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis and Drug-Induced Ductopenias","volume":"11","author":"Wu","year":"2004","journal-title":"Clin. Dev. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/gut.34.9.1245","article-title":"Intercellular Adhesion Molecule-1 and MHC Antigens on Human Intrahepatic Bile Duct Cells: Effect of pro-Inflammatory Cytokines","volume":"34","author":"Ayres","year":"1993","journal-title":"Gut"},{"key":"ref_55","first-page":"485","article-title":"Tumor Necrosis Factor-\u03b1-Induced Apoptosis in Hepatocytes in Long-Term Culture","volume":"148","author":"Bour","year":"1996","journal-title":"Am. J. Pathol."},{"key":"ref_56","first-page":"925","article-title":"Peptide Antibiotic Human Beta-Defensin-1 and -2 Contribute to Antimicrobial Defense of the Intrahepatic Biliary Tree","volume":"40","author":"Harada","year":"2004","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/01.LAB.0000097190.56734.FE","article-title":"Lipopolysaccharide Activates Nuclear Factor-KappaB through Toll-like Receptors and Related Molecules in Cultured Biliary Epithelial Cells","volume":"83","author":"Harada","year":"2003","journal-title":"Lab. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00441-010-1022-4","article-title":"Defensins in Innate Immunity","volume":"343","author":"Hazlett","year":"2011","journal-title":"Cell Tissue Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/hep.21792","article-title":"Transforming Growth Factor-\u03b2 and Substrate Stiffness Regulate Portal Fibroblast Activation in Culture","volume":"46","author":"Li","year":"2007","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4161\/19336918.2014.972788","article-title":"Extracellular Matrix as a Contextual Determinant of Transforming Growth Factor-\u03b2 Signaling in Epithelial-Mesenchymal Transition and in Cancer","volume":"8","author":"Cichon","year":"2014","journal-title":"Cell Adh. Migr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/hep.25691","article-title":"Up-Regulation of MicroRNA 506 Leads to Decreased Cl-\/HCO3- Anion Exchanger 2 Expression in Biliary Epithelium of Patients with Primary Biliary Cirrhosis","volume":"56","author":"Banales","year":"2012","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and Functional Analysis of PDC-E2-Specific Autoreactive Cytotoxic T Lymphocytes in Primary Biliary Cirrhosis","volume":"109","author":"Kita","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"100530","DOI":"10.1016\/j.aohep.2021.100530","article-title":"Mechanism of Cholangiocellular Damage and Repair during Cholestasis","volume":"26","author":"Bucio","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.36290\/vnl.2020.084","article-title":"Chronic Cholestatic Liver Diseases\u2014Primary Biliary Cholangitis and Primary Sclerosing Cholangitis","volume":"66","author":"Fejfar","year":"2020","journal-title":"Vnitr. Lek."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12016-019-08731-2","article-title":"Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis","volume":"58","author":"Chen","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"101291","DOI":"10.1016\/j.plipres.2024.101291","article-title":"Immunology of Bile Acids Regulated Receptors","volume":"95","author":"Fiorucci","year":"2024","journal-title":"Prog. Lipid Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Biagioli, M., Di Giorgio, C., Massa, C., Marchian\u00f2, S., Bellini, R., Bordoni, M., Urbani, G., Roselli, R., Lachi, G., and Morretta, E. (2024). A Microbial Derived Bile Acid Acts as GPBAR1 Agonist and ROR\u03b3t Inverse Agonist and Reverses Inflammation in Inflammatory Bowel Disease. bioRxiv.","DOI":"10.1101\/2024.04.08.588556"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1053\/j.gastro.2004.08.006","article-title":"The Cholangiopathies: Disorders of Biliary Epithelia","volume":"127","author":"Lazaridis","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mayocp.2015.03.017","article-title":"The Cholangiopathies","volume":"90","author":"Lazaridis","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.37349\/edd.2023.00028","article-title":"Interplay of Autophagy, Apoptosis, and Senescence in Primary Biliary Cholangitis","volume":"2","author":"Kouroumalis","year":"2023","journal-title":"Explor. Dig. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1590\/1519-6984.228437","article-title":"Apoptosis (Programmed Cell Death) and Its Signals\u2014A Review","volume":"81","author":"Obeng","year":"2021","journal-title":"Braz. J. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/cr.2007.52","article-title":"Apoptosis Signaling Pathways and Lymphocyte Homeostasis","volume":"17","author":"Xu","year":"2007","journal-title":"Cell Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"50","DOI":"10.12729\/jbtr.2020.21.2.050","article-title":"Flavonoid-Induced Apoptotic Cell Death in Human Cancer Cells and Its Mechanisms","volume":"21","author":"Bhosale","year":"2020","journal-title":"J. Biomed. Transl. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41577-019-0167-y","article-title":"How Macrophages Deal with Death","volume":"19","author":"Lemke","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cbin.11137","article-title":"Cell Death: A Review of the Major Forms of Apoptosis, Necrosis and Autophagy","volume":"43","year":"2019","journal-title":"Cell Biol. Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.510260604","article-title":"Enhanced Apoptosis Relates to Bile Duct Loss in Primary Biliary Cirrhosis","volume":"26","author":"Harada","year":"1997","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/hep.510250505","article-title":"Nuclear DNA Fragmentation and Expression of Bcl-2 in Primary Biliary Cirrhosis","volume":"25","author":"Koga","year":"1997","journal-title":"Hepatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e88747","DOI":"10.1172\/jci.insight.88747","article-title":"Preferential TNF\u03b1 Signaling via TNFR2 Regulates Epithelial Injury and Duct Obstruction in Experimental Biliary Atresia","volume":"2","author":"Shivakumar","year":"2017","journal-title":"JCI Insight"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jhep.2018.08.015","article-title":"Inactivation of Caspase 8 in Liver Parenchymal Cells Confers Protection against Murine Obstructive Cholestasis","volume":"69","author":"Cubero","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/cei.12032","article-title":"CXCR3 Axis in Patients with Primary Biliary Cirrhosis: A Possible Novel Mechanism of the Effect of Ursodeoxycholic Acid","volume":"172","author":"Manousou","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/hep.20246","article-title":"Tauroursodeoxycholic Acid Protects Rat Hepatocytes from Bile Acid-Induced Apoptosis via Activation of Survival Pathways","volume":"39","author":"Schoemaker","year":"2004","journal-title":"Hepatology"},{"key":"ref_82","first-page":"958","article-title":"Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis: From Bench to Bedside","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100182","DOI":"10.1016\/j.jtauto.2022.100182","article-title":"Apoptotic Biliary Epithelial Cells and Gut Dysbiosis in the Induction of Murine Primary Biliary Cholangitis","volume":"6","author":"Wang","year":"2023","journal-title":"J. Transl. Autoimmun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.molmed.2009.09.005","article-title":"P53 and the Regulation of Hepatocyte Apoptosis: Implications for Disease Pathogenesis","volume":"15","author":"Amaral","year":"2009","journal-title":"Trends Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"18698","DOI":"10.1074\/jbc.RA119.010176","article-title":"The Transcription Factor ETS1 Promotes Apoptosis Resistance of Senescent Cholangiocytes by Epigenetically Up-Regulating the Apoptosis Suppressor BCL2L1","volume":"294","author":"Splinter","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Meadows, V., Baiocchi, L., Kundu, D., Sato, K., Fuentes, Y., Wu, C., Chakraborty, S., Glaser, S., Alpini, G., and Kennedy, L. (2021). Biliary Epithelial Senescence in Liver Disease: There Will Be SASP. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.803098"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Cuollo, L., Antonangeli, F., Santoni, A., and Soriani, A. (2020). The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases. Biology, 9.","DOI":"10.3390\/biology9120485"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression","volume":"5","author":"Desprez","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s00535-014-1033-0","article-title":"A Possible Involvement of Endoplasmic Reticulum Stress in Biliary Epithelial Autophagy and Senescence in Primary Biliary Cirrhosis","volume":"50","author":"Sasaki","year":"2015","journal-title":"J. Gastroenterol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/hep.22348","article-title":"Telomere Shortening in the Damaged Small Bile Ducts in Primary Biliary Cirrhosis Reflects Ongoing Cellular Senescence","volume":"48","author":"Sasaki","year":"2008","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"102377","DOI":"10.1016\/j.jaut.2019.102377","article-title":"Increased P16(INK4a)-Expressing Senescent Bile Ductular Cells Are Associated with Inadequate Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis","volume":"107","author":"Sasaki","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbalip.2019.07.006","article-title":"Ursodeoxycholic Acid Is a GPBAR1 Agonist and Resets Liver\/Intestinal FXR Signaling in a Model of Diet-Induced Dysbiosis and NASH","volume":"1864","author":"Carino","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Marchian\u00f2, S., Biagioli, M., Morretta, E., Di Giorgio, C., Roselli, R., Bordoni, M., Bellini, R., Urbani, G., Massa, C., and Monti, M.C. (2023). Combinatorial Therapy with BAR502 and UDCA Resets FXR and GPBAR1 Signaling and Reverses Liver Histopathology in a Model of NASH. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-28647-4"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000371864","article-title":"The Cholangiocyte Glycocalyx Stabilizes the \u201cBiliary HCO3 Umbrella\u201d: An Integrated Line of Defense against Toxic Bile Acids","volume":"33","author":"Hohenester","year":"2015","journal-title":"Dig. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gutjnl-2018-316975","article-title":"TGR5-Dependent Hepatoprotection through the Regulation of Biliary Epithelium Barrier Function","volume":"69","author":"Merlen","year":"2020","journal-title":"Gut"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"H114-26","DOI":"10.1152\/ajpheart.00087.2015","article-title":"Cystathionine \u03b3-Lyase, a H2S-Generating Enzyme, Is a GPBAR1-Regulated Gene and Contributes to Vasodilation Caused by Secondary Bile Acids","volume":"309","author":"Renga","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Renga, B., Cipriani, S., Carino, A., Simonetti, M., Zampella, A., and Fiorucci, S. (2015). Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT\/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141082"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G-Protein-Coupled Bile Acid Receptor, Gpbar1 (TGR5), Negatively Regulates Hepatic Inflammatory Response through Antagonizing Nuclear Factor \u03ba Light-Chain Enhancer of Activated B Cells (NF-\u039aB) in Mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbrc.2008.04.171","article-title":"Expression and Function of the Bile Acid Receptor TGR5 in Kupffer Cells","volume":"372","author":"Keitel","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, F., Xiao, X., Li, Y., Wu, H., Deng, X., Jiang, Y., Zhang, W., Wang, J., Ma, X., and Zhao, Y. (2022). Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.805269"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10620-020-06715-3","article-title":"Bile Acid Signaling in Inflammatory Bowel Diseases","volume":"66","author":"Fiorucci","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Fiorucci, S., Biagioli, M., Zampella, A., and Distrutti, E. (2018). Bile Acids Activated Receptors Regulate Innate Immunity. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01853"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary Biliary Cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Floreani, A., Gabbia, D., and De Martin, S. (2022). Update on the Pharmacological Treatment of Primary Biliary Cholangitis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10082033"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/00042737-199910000-00001","article-title":"Optimum Dose of Ursodeoxycholic Acid in Primary Biliary Cirrhosis","volume":"11","author":"Verma","year":"1999","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_106","first-page":"CD000551","article-title":"Ursodeoxycholic Acid for Primary Biliary Cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Marchian\u00f2, S., Biagioli, M., Roselli, R., Zampella, A., Di Giorgio, C., Bordoni, M., Bellini, R., Urbani, G., Morretta, E., and Monti, M.C. (2022). Beneficial Effects of UDCA and NorUDCA in a Rodent Model of Steatosis Are Linked to Modulation of GPBAR1\/FXR Signaling. Biochim. Biophys. Mol. Cell Biol. Lipids, 1867.","DOI":"10.1016\/j.bbalip.2022.159218"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.4049\/jimmunol.1901427","article-title":"The Bile Acid Receptor GPBAR1 Modulates CCL2\/CCR2 Signaling at the Liver Sinusoidal\/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity","volume":"204","author":"Biagioli","year":"2020","journal-title":"J. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","article-title":"FXR Inhibition May Protect from SARS-CoV-2 Infection by Reducing ACE2","volume":"615","author":"Brevini","year":"2023","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/er.2000-0035","article-title":"Bile Acid Regulation of Gene Expression: Roles of Nuclear Hormone Receptors","volume":"23","author":"Chiang","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Panzitt, K., and Wagner, M. (2021). FXR in Liver Physiology: Multiple Faces to Regulate Liver Metabolism. Biochim. Biophys. Acta\u2014Mol. Basis Dis., 1867.","DOI":"10.1016\/j.bbadis.2021.166133"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbadis.2009.04.004","article-title":"Reciprocal Regulation of the Bile Acid-Activated Receptor FXR and the Interferon-Gamma-STAT-1 Pathway in Macrophages","volume":"1792","author":"Renga","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X Receptor Antagonizes Nuclear Factor \u039aB in Hepatic Inflammatory Response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous Hepatocarcinogenesis in Farnesoid X Receptor-Null Mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous Development of Liver Tumors in the Absence of the Bile Acid Receptor Farnesoid X Receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00011-010-0306-1","article-title":"SHP-Dependent and -Independent Induction of Peroxisome Proliferator-Activated Receptor-\u03b3 by the Bile Acid Sensor Farnesoid X Receptor Counter-Regulates the pro-Inflammatory Phenotype of Liver Myofibroblasts","volume":"60","author":"Renga","year":"2011","journal-title":"Inflamm. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The Nuclear Receptor SHP Mediates Inhibition of Hepatic Stellate Cells by FXR and Protects against Liver Fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2015.01.045","article-title":"Interactions Between Nuclear Receptor SHP and FOXA1 Maintain Oscillatory Homocysteine Homeostasis in Mice","volume":"148","author":"Tsuchiya","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","article-title":"Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X Receptor Modulators 2014-Present: A Patent Review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile Acid Modulators for the Treatment of Nonalcoholic Steatohepatitis (NASH)","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"11323","DOI":"10.1073\/pnas.0604772103","article-title":"Benefit of Farnesoid X Receptor Inhibition in Obstructive Cholestasis","volume":"103","author":"Stedman","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbagrm.2011.01.008","article-title":"Farnesoid X Receptor Suppresses Constitutive Androstane Receptor Activity at the Multidrug Resistance Protein-4 Promoter","volume":"1809","author":"Renga","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Renga, B., Mencarelli, A., D\u2019Amore, C., Cipriani, S., D\u2019Auria, M.V., Sepe, V., Chini, M.G., Monti, M.C., Bifulco, G., and Zampella, A. (2012). Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030443"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1021\/jm101336m","article-title":"Discovery of Sulfated Sterols from Marine Invertebrates as a New Class of Marine Natural Antagonists of Farnesoid-X-Receptor","volume":"54","author":"Sepe","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls","volume":"163","author":"Fisher","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients with Primary Biliary Cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19768354.2016.1211175","article-title":"Essential Roles of Bile Acids and Their Nuclear Receptors, FXR and PXR, in the Cholestatic Liver Disease","volume":"20","author":"Han","year":"2016","journal-title":"Animal Cells Syst."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of Fibrates with Obeticholic Acid Is Able to Normalise Biochemical Liver Tests in Patients with Difficult-to-Treat Primary Biliary Cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.abb.2012.04.001","article-title":"Where Is the Vitamin D Receptor?","volume":"523","author":"Wang","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1210\/jc.2008-1454","article-title":"Nonclassic Actions of Vitamin D","volume":"94","author":"Bikle","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1053\/jhep.2003.50176","article-title":"The Normal Liver Harbors the Vitamin D Nuclear Receptor in Nonparenchymal and Biliary Epithelial Cells","volume":"37","author":"Demers","year":"2003","journal-title":"Hepatology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D Receptor as an Intestinal Bile Acid Sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.4049\/jimmunol.179.3.1634","article-title":"Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation","volume":"179","author":"Chen","year":"2007","journal-title":"J. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.4049\/jimmunol.0801543","article-title":"Calcitriol Suppresses Antiretinal Autoimmunity through Inhibitory Effects on the Th17 Effector Response","volume":"182","author":"Tang","year":"2009","journal-title":"J. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1182\/blood-2005-05-2044","article-title":"Expression of the Inhibitory Receptor ILT3 on Dendritic Cells Is Dispensable for Induction of CD4+Foxp3+ Regulatory T Cells by 1,25-Dihydroxyvitamin D3","volume":"106","author":"Penna","year":"2005","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cyto.2008.12.009","article-title":"1Alpha,25-Dihydroxyvitamin D3 Inhibits CD40L-Induced pro-Inflammatory and Immunomodulatory Activity in Human Monocytes","volume":"45","author":"Almerighi","year":"2009","journal-title":"Cytokine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","article-title":"A Vitamin D Receptor\/SMAD Genomic Circuit Gates Hepatic Fibrotic Response","volume":"153","author":"Ding","year":"2013","journal-title":"Cell"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Kempinska-Podhorodecka, A., Milkiewicz, M., Wasik, U., Ligocka, J., Zawadzki, M., Krawczyk, M., and Milkiewicz, P. (2017). Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-MiRNA155-SOCS1 Pathway. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020289"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-Omics of the Gut Microbial Ecosystem in Inflammatory Bowel Diseases","volume":"569","author":"Arze","year":"2019","journal-title":"Nature"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.chom.2021.07.013","article-title":"A Bacterial Bile Acid Metabolite Modulates T(Reg) Activity through the Nuclear Hormone Receptor NR4A1","volume":"29","author":"Li","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile Acid Metabolites Control T(H)17 and T(Reg) Cell Differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/mol.117.110155","article-title":"PXR: More Than Just a Master Xenobiotic Receptor","volume":"93","author":"Oladimeji","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2624941","DOI":"10.1155\/2019\/2624941","article-title":"Nuclear Receptors in the Pathogenesis and Management of Inflammatory Bowel Disease","volume":"2019","author":"Ning","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bcp.2010.08.022","article-title":"Pregnane-X-Receptor Mediates the Anti-Inflammatory Activities of Rifaximin on Detoxification Pathways in Intestinal Epithelial Cells","volume":"80","author":"Mencarelli","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejphar.2011.06.058","article-title":"Inhibition of NF-\u039aB by a PXR-Dependent Pathway Mediates Counter-Regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells","volume":"668","author":"Mencarelli","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1073\/pnas.0409794102","article-title":"Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Ameliorate Cholestatic Liver Injury","volume":"102","author":"Stedman","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bjp.0707235","article-title":"Hepatoprotective Role of PXR Activation and MRP3 in Cholic Acid-Induced Cholestasis","volume":"151","author":"Teng","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of Long-Term Rifampicin Administration in Primary Biliary Cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1021\/jm200169t","article-title":"Theonellasterols and Conicasterols from Theonella Swinhoei. Novel Marine Natural Ligands for Human Nuclear Receptors","volume":"54","author":"Ummarino","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Okamura, M., Shizu, R., Abe, T., Kodama, S., Hosaka, T., Sasaki, T., and Yoshinari, K. (2020). PXR Functionally Interacts with NF-\u039aB and AP-1 to Downregulate the Inflammation-Induced Expression of Chemokine CXCL2 in Mice. Cells, 9.","DOI":"10.3390\/cells9102296"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jcmgh.2023.12.005","article-title":"Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts","volume":"17","author":"Schnabl","year":"2024","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Zhang, J., Wu, G., Tang, Y., Liu, H., Ge, X., Peng, R., Cao, J., Tu, D., Su, B., and Jin, S. (2023). Causal Associations between Gut Microbiota and Primary Biliary Cholangitis: A Bidirectional Two-Sample Mendelian Randomization Study. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1273024"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut Microbial Profile Is Altered in Primary Biliary Cholangitis and Partially Restored after UDCA Therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.gastro.2024.05.014","article-title":"Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis in Primary Biliary Cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early Primary Biliary Cirrhosis: Biochemical Response to Treatment and Prediction of Long-Term Outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved Prognosis of Patients with Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent Long-Term Survival in Patients with Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo Risk Score in Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, and Clinical Practice Guideline Panel (2021). EASL Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis\u20142021 Update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver Stiffness Measurement by Vibration-Controlled Transient Elastography Improves Outcome Prediction in Primary Biliary Cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Cipriani, S., Renga, B., D\u2019Amore, C., Simonetti, M., De Tursi, A.A., Carino, A., Monti, M.C., Sepe, V., Zampella, A., and Fiorucci, S. (2015). Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129866"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJMe2313802","article-title":"PPAR Agonists in Primary Biliary Cholangitis","volume":"390","author":"Schnabl","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha\/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"111650","DOI":"10.1016\/j.mce.2022.111650","article-title":"Immunomodulatory Functions of FXR","volume":"551","author":"Fiorucci","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A Multi-Society Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJMe2312745","article-title":"Advancing Second-Line Treatment for Primary Biliary Cholangitis","volume":"390","author":"Assis","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients with Pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-Concept Study to Evaluate the Safety and Efficacy of Saroglitazar in Patients with Primary Biliary Cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","article-title":"Effectiveness of Fenofibrate in Treatment-Naive Patients with Primary Biliary Cholangitis: A Randomized Clinical Trial","volume":"118","author":"Liu","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.30099","article-title":"Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial","volume":"70","author":"Khanna","year":"2019","journal-title":"Hepatology"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e001001","DOI":"10.1136\/bmjgast-2022-001001","article-title":"Feasibility, Safety and Tolerability of the CREB-Binding Protein\/\u03b2-Catenin Inhibitor OP-724 in Patients with Advanced Primary Biliary Cholangitis: An Investigator-Initiated, Open-Label, Non-Randomised, Two-Centre, Phase 1 Study","volume":"9","author":"Kimura","year":"2022","journal-title":"BMJ open Gastroenterol."},{"key":"ref_184","first-page":"1507","article-title":"Setanaxib, a First-in-Class Selective NADPH Oxidase 1\/4 Inhibitor for Primary Biliary Cholangitis: A Randomized, Placebo-Controlled, Phase 2 Trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"6691425","DOI":"10.1155\/2021\/6691425","article-title":"Ursodeoxycholic Acid at 18-22\u2009Mg\/Kg\/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis","volume":"2021","author":"Xiang","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A Placebo-Controlled Randomised Trial of Budesonide for PBC Following an Insufficient Response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Al-Dury, S., Wahlstr\u00f6m, A., Wahlin, S., Langedijk, J., Elferink, R.O., St\u00e5hlman, M., and Marschall, H.-U. (2018). Pilot Study with IBAT Inhibitor A4250 for the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-25214-0"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial","volume":"160","author":"Bolier","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1574887114666190328130720","article-title":"Comparison of Sertraline with Rifampin in the Treatment of Cholestatic Pruritus: A Randomized Clinical Trial","volume":"14","author":"Ataei","year":"2019","journal-title":"Rev. Recent. Clin. Trials"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The Pharmacology of Bile Acids and Their Receptors","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/hepr.13931","article-title":"Determinants of the Effectiveness of Bezafibrate Combined with Ursodeoxycholic Acid in Patients with Primary Biliary Cholangitis","volume":"53","author":"Matsumoto","year":"2023","journal-title":"Hepatol. Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/18\/1580\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:59:55Z","timestamp":1760111995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/18\/1580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":191,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cells13181580"],"URL":"https:\/\/doi.org\/10.3390\/cells13181580","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}